STRATEGIC ALLIANCES
Oncolix has acquired its technologies from the
Greenville Hospital System (GHS), who receives a small management fee to cover
the company's administrative costs. A substantial discount on fees relating to
clinical trials conducted at GHS’s clinical trial unit is available to Oncolix.
Oncolix has chosen BioVectra, Inc. to perform the manufacturing
of Prolanta. BioVectra is the largest Canadian company manufacturing both large
and small-molecule Advanced Pharmaceutical Ingredients (API's), advanced
intermediates, and cGMP bioprocessing reagents. With 40 years experience in
serving the pharmaceutical and biopharmaceutical industries, clients range from
small drug development entities to many of the world's largest multinational
health care companies.
Oncolix is a member of BIO and BioHouston.
BIO is the world's largest
biotechnology organization, providing advocacy, business development and
communications services for more than 1,200 members worldwide. BioHouston is
the hub of an active and growing life science cluster. Academic and research
institutions connect with life science companies and service providers to build
successful companies and ultimately products that save and improve lives.
Oncolix welcomes interest in developing a technical or financial
partnership with both public and private entities that are symbiotic and will
allow Prolanta™ to reach the market.
Contact us today.
